Management of hypertension
In their interesting investigation on prescribing in hypertension (April 1991 JRSM, p 203), Feher and Lant seem to take for granted three important points: (I) Some antihypertensive drugs (diuretics, betablockers) have metabolic adverse effects; (2) Other antihypertensive drugs (ACE inhibitors) are virtually devoid of these metabolic effects; and (3) Pharmacological treatment of hypertension has produced no significant reduction of coronary heart disease (CHD), and the metabolic adverse effects of the drugs used may have contributed to this relative failure. However, evidence for each of these points is far from being convincing. It is not certain that diuretics or beta-blockers have all the same potential for inducing adverse effects on glucose or lipid metabolism. For example, it is generally recognized that effects of this type are small and transient with spironolactone'. Likewise, beta-blockers with intrinsic sympathomimetic activity are said to produce the smallest changes in serum lipids'',
We do not know whether the metabolic safety is a class or an agent-specific property. When the number of available ACE inhibitors will be as great as that of diuretics or of beta-blockers, it may happen that some will reveal a deleterious profile on metabolic parameters.
The question of the reduction of CHD in patients on antihypertensive therapy is highly controversial. Lack of clear benefit of antihypertensive drugs may be due'': (a) to insufficient sample size in published trials; (b) to insufficient duration of follow-up; (c) to adverse effects of the drugs used: metabolic effects, possibly, but also arrhythmias due to a loss of potassium, etc. It has to be emphasized that the long-term consequences of the metabolic effects of antihypertensive drugs are not known.
Another controversial issue remains too frequently overlooked; safe or not, ACE inhibitors have given absolutely no evidence of their interest in the longterm treatment of hypertension, neither in reducing CHD ... nor in reducing stroke! Therefore, the prescribing behaviour of practitioners may be interpreted in different ways: (a) it may result from their lack of information; (b) it may result from a difficulty in changing their current practice, as it has already been noted in other medical situations': (c) it may reflect a wise pragmatism, and a well-founded reluctance towards premature extrapolations of equivocal results from clinical pharmacology. M GIRARD 19 rue de la Glaciere 75013 Paris, France
